Showing results (1-10 of 6) with videos related to
Sort By:
Pageof 1
Expert Opinion on Investigational Drugs|July 1, 2020
Enhancing venetoclax activity in hematological malignanciesToshihisa Satta, Steven GrantBest Practice & Research. Clinical Haematology|October 9, 2021
Clinical experience of CAR T cells for multiple myelomaGary L Simmons, Toshihisa Satta, Omar Castaneda PuglianiniClinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 18, 2023
Dual mTORC1/2 Inhibition Synergistically Enhances AML Cell Death in Combination with the BCL2 Antagonist VenetoclaxToshihisa Satta, Lin Li, Sri Lakshmi Chalasani, et al.Clinical Lymphoma, Myeloma & Leukemia|October 22, 2017
Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple MyelomaAjai Chari, Suzanne Arinsburg, Sundar Jagannath, et al.Hematological Oncology|July 5, 2022
Mechanisms underlying synergism between circularized tumor necrosis factor-related apoptosis inducing ligand and bortezomib in bortezomib-sensitive or -resistant myeloma cellsYun Leng, Xiaoyan Hu, Lin Li, et al.Journal for Immunotherapy of Cancer|September 15, 2025
Pre-infusion risk factors predict severe infectious complications of CAR T-cell therapy in pediatric and adult patients with B-ALLAugust A Culbert, Flavia Gava, Yannis K Valtis, et al.Pageof 1